

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> <b>A61K 9/00, 9/20, 31/52</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/02662</b> <b>(43) International Publication Date:</b> <b>18 February 1993 (18.02.93)</b>
<b>(21) International Application Number:</b> <b>PCT/EP92/01655</b>		<b>(81) Designated States:</b> AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).	
<b>(22) International Filing Date:</b> <b>20 July 1992 (20.07.92)</b>			
<b>(30) Priority data:</b> <b>MI91A002071 26 July 1991 (26.07.91) IT</b>		<b>Published</b> <i>With international search report.</i>	
<b>(71) Applicant (for all designated States except US):</b> L.C. PHAR-CHEM LTD. [CY/CY]; Chanteclair House, Suite 111, 28 Sophoulis Street, Nicosia (CY).			
<b>(72) Inventors; and</b>			
<b>(75) Inventors/Applicants (for US only) :</b> CONTE, Ubaldo [IT/IT]; Via Treviglio, 6, I-21052 Busto Arsizio (IT). MAGGI, Lauretta [IT/IT]; Via Folporti, 3, I-27100 Pavia (IT).			
<b>(74) Agent:</b> MINOJA, Fabrizio; Studio Consulenza Brevetti-ale, Via Rossini, 8, I-20122 Milano (IT).			

**(54) Title:** ANTIVIRAL PHARMACEUTICAL COMPOSITIONS FOR VAGINAL ADMINISTRATION

**(57) Abstract**

Biocompatible sustained-release vaginal antiviral compositions in form of effervescent tablets, bioadhesive tablets, bi-layered tablets, bioadhesive washes, are described.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

ANTIVIRAL PHARMACEUTICAL COMPOSITIONS FOR VAGINAL  
ADMINISTRATION

The present invention refers to antiviral pharmaceutical compositions for vaginal administration.

Particular attention has been recently paid to the administration of drugs by the vaginal route in order 5 to obtain, beside local effects, also systemic effects.

Usually, the drug is carried in form of vaginal ovules comprising semisynthetic glycerides (Remington's Pharmaceutical Sciences 17 Ex. p. 582) or natural fats (e.g. cocoa butter) having normally a melting or 10 softening point at about 37°C, allowing the release of the drug for the absorption.

The drug may be solubilized in the fatty components or it may be homogeneously dispersed therein.

15 Other known forms for vaginal use include soft capsules, suited for non-hydrophilic, liquid drugs, oily dispersions or solutions, vaginal washes, ointments, gels.

20 The known compositions are not satisfactory since they cannot provide a sufficiently long permanence of the drug in contact with the vaginal mucosa.

Antiviral drugs are particularly suited for the vaginal administration.

25 The present invention provides prompt and/or sustained release antiviral compositions for vaginal administrations.

The sustained or prolonged release after vaginal administration may be obtained according to the

invention by means of effervescent compositions; slowly erodible and/or disintegrating hydrophilic tablets; bioadhesive, hydrophilic tablets; bi-layered tablets wherein a first layer is able to release immediately 5 the drug and the second layer provides the sustained release of the drug by means of bioadhesive biocompatible polymers; washes, gels or ointments containing biocompatible bioadhesive polymers.

Example of antiviral drugs which may be used 10 according to the invention include: acycloguanosine (acyclovir) or its salts or derivatives, trifluridine, bromovinyldeoxyuridine, desciclovir, enviroxime, fo-scarnet sodium, ganciclovir, idoxuridine, inosine pranobex, interferons ( $\alpha$ ,  $\beta$ ,  $\gamma$ ), rimantadine 15 hydrochloride, ribavirine, vidarabine and derivatives, zidovudine or azidothymidine.

Acycloguanosine or acyclovir (The Extra Pharmacopoeia 29<sup>th</sup> Ed., p. 689) is particularly preferred.

According to a first preferred embodiment, the 20 invention provides therefore antiviral vaginal tablets formulated so as to cause, when in contact with the liquids present in the application site, a slight, progressive and slow effervescence. The selection of 25 the appropriate amounts of a organic and biocompatible acid and of an alkaline carbonate or bicarbonate will provide the desired effect.

A second preferred embodiment is provided by 30 vaginal tablets releasing the drug in a period from some hours to some days, thanks to suitable hydrophilic polymers. Examples of said hydrophilic polymers

include: xantanes, galactomannanes, carboxyvinyl-polymers, cellulose derivatives such as methylcellulose, ethylcellulose, sodium carboxymethyl-cellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose.

Preferably hydroxypropylmethylcelluloses characterized by different average molecular weights and viscosities (generally measured on 2 w% aqueous solutions with a suitable viscosimeter), can be used.

Also hydroxypropylmethylcelluloses with the same average molecular weight, but with different degree of substitution or different methoxyl/hydroxypropoxyl substituent ratio can be used, having therefore different gellable and/or erodible characteristics. As a consequence the dosage forms formulated with these polymers can show different solubilization rates and different retention times in the administration site.

Hydroxypropylmethylcelluloses commercial products are characterized by different methoxyl/hydroxypropoxyl substituent ratios (namely the substituents of the anhydroglucose units of cellulose) that influences aqueous/organic solubility and terminal gel point temperature of aqueous solutions. As an example the hydroxypropylmethylcellulose marketed with the trade mark of Methocel® type E, type F and type K, is characterized by different propylene glycol ether to methoxyl substitution ratios on the same polymer backbone, and, moreover, each type is produced in wide range of average molecular weights.

Said polymers can be employed in the formulation in a percentage ranging from 5 to 95% (depending on

drug solubility and as a function of the programmed drug release rate from the dosage form), but preferably this polymers are used in amounts varying from 15 to 60 w/w%.

5 A further preferred embodiment is provided by pharmaceutical forms devised for a pulsing release of the drug, i.e. able to release immediately a first portion of the drug and a second portion in a prolonged period of time. It is therefore possible a simpler  
10 posology and a better patient compliance. This kind of formulation may consist in bi-layered tablets as defined above. Still a further preferred embodiment is provided by vaginal tablets comprising bioadhesive polymers such as gelatine, xantanes, scleroglucane,  
15 collagene, pectine and amylopectine, dextrans, hyaluronic or polygalactouronic acid, alginic acid, alginates, polyvinylpyrrolidone, polyvinylalcohol, polyethyleneglycols, polypropyleneglycols and copolymers, polymethylvinylether maleic anhydride copolymer and  
20 derivatives, polyacrylic and methacrylic acid derivatives, carboxyvinylpolymers, cellulose derivatives: methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and its salts.  
25

These bioadhesive properties of said polymers may be determined by the methods disclosed in S.T.P. Pharma 4 (8) 688-697, 1988.

30 The adhesive and bioadhesive properties of the formulations reported below were tested using a suitable apparatus described in a previous work (Maggi, L., Giunchedi, P., Conte, U., La Manna, A., Acta

Technol. Legis Medic., 3, 13, 1992). The procedure consists of two steps: sample and substrate conditioning for adhesion setting, and fracture strength determination. The sample is fixed to the holder and  
5 wetted with a defined volume of hydration fluid (mucin 2 w% aqueous solution). The sample is let to hydrate for 5 minutes, then the holder is rised towards the probe (quartz load washer), till the contact between the two surfaces is established. At this point a  
10 preload of 0.15 kg/cm<sup>2</sup> is applied for 2 minutes in order to establish adhesion bindings. The measurement starts when the holder is lowered at a constant speed, and ends when the two substrates are completely detached. A negative peak is obtained, maximum value of  
15 which represents the adhesive strenght.

The biocompatible bioadhesive polymers may also be used for semisolid formulations such as ointments, gels and the like.

These compositions contains the active component  
20 in an amount from 0.5 to 50% w/w and the classical excipients for gels or hydrophilic or lipophilic ointments (such as cellulose derivatives, carboxyethyl-cellulose, carboxyvinylpolymers) or special polymers such poloxamer (polyoxyethylene polyoxypropylene  
25 copolymers) with molecular weight higher than 3000 (such as Pluronic F 108, F 127, F 98, F 88 ecc.) and poloxamines (copolymers oxypropylene-oxyethylene-ethylenediamine) (Tetronic) used as gelifying agents in amounts ranging from 10 to 60% and characterized by  
30 sensitivity to temperature changes.

Particularly, Pluronic F 127, used in solution in

a suitable amount, has a low viscosity at room temperature whereas remarkably increases its viscosity at temperatures of 35-37°C. This causes a more stiff structure of the gelified medium and, as a consequence, 5 the drug is released during a longer period of time.

For the preparation of tablets or other pharmaceutical forms for vaginal administration, excipients and technological additives suited to confer to the compositions the desired flowability and 10 compactation characteristics as well as components useful to make the composition aesthetically acceptable, may also be used.

In order to evaluate the therapeutic characteristics of the compositions of the invention, 15 clinical trials were carried out on vaginal effervescent tablets or slow-release bi-layered vaginal tablets containing 400 mg of acyclovir.

The results of the tests, carried out on 40 patients affected by relapsing Type 2 genital herpes treated with one tablet per day of Examples 1, 3 or 4, 20 have shown that the compositions of the invention are able to induce the regression of symptomatology more rapidly and with a better tolerability in comparison with the conventional vaginal formulations.

25 The invention is further illustrated by the following Examples.

EXAMPLE 1Effervescent tablets containing acyclovirUnitary composition:

5	acyclovir	400.0 mg
	lactose	900.0 mg
	maize starch	242.0 mg
	adipic acid	140.0 mg
	sodium bicarbonate	110.0 mg
10	magnesium stearate	20.0 mg
	stearic acid	8.0 mg
	colloidal silica	8.0 mg
	polysorbate 80	2.0 mg

15 Preparation

A granulate containing the active principle is prepared by mixing acyclovir and maize starch together with an aqueous solution of starch paste and polysorbate 80.

20 The wet mass is forced through a screen (710 µ). The granulate is then dried to constant weight and sieved again.

Colloidal silica is added thereto and the mixture is mixed in a solid mixer for 10 minutes. Separately, a 25 granulate containing adipic acid is prepared from lactose and maize starch. The two granulates are then mixed together in a powder mixer for 15 minutes. Sodium bicarbonate is then added and mixed for further 15 minutes. Stearic acid, magnesium stearate and colloidal 30 silica (previously sieved) are finally added and mixed for further 20 minutes.

Tablets having ogival or almond shape and containing 400 mg of active principle are prepared from the obtained mixture.

EXAMPLE 2

	<u>Sustained-release formulation</u>	<u>bioadhesive</u>	<u>acyclovir</u>	<u>vaginal</u>
5				
	<u>Unitary composition</u>			
	acyclovir			200 mg
	hydroxypropylmethylcellulose			
10	(Methocel K 4 M)			200 mg
	mannitol			400 mg
	maize starch			400 mg
	adipic acid			70 mg
	talc			20 mg
15	magnesium stearate			10 mg

The active component, hydroxypropylmethylcellulose, mannitol, maize starch and adipic acid, previously sieved on a 250  $\mu$  screen, are mixed for 20 minutes in a suitable powder mixer. The mixture is then added with magnesium stearate and talc and mixed for further 20 minutes.

Ogival tablets containing 200 mg of acyclovir are prepared from this mixture.

EXAMPLE 3

	<u>Sustained-release formulation</u>	<u>bioadhesive</u>	<u>acyclovir</u>	<u>vaginal</u>
5	acyclovir sodium salt equivalent to acyclovir hydroxypropylmethylcellulose (Methocel K 4 M)		400 mg	
	mannitol		200 mg	
	maize starch		300 mg	
10	adipic acid		300 mg	
	talc		70 mg	
	magnesium stearate		20 mg	
			10 mg	

Ogival tablets containing 400 mg of acyclovir are  
15 prepared by essentially the same method of Example 2.

EXAMPLE 4Bi-layered vaginal tablets containing acyclovir

A first layer, effervescent, has the following  
unitary composition:

20	-----	-----
	acyclovir	200.0 mg
	lactose	500.0 mg
	maize starch	122.0 mg
	adipic acid	70.0 mg
25	sodium bicarbonate	55.0 mg
	magnesium stearate	10.0 mg
	stearic acid	4.0 mg
	colloidal silica	4.0 mg
	polysorbate 80	1.0 mg
30	-----	-----

The granulate is prepared according to the method of Example 1.

The second layer has the following unitary composition.

5

	acyclovir	200 mg
	hydroxypropylmethylcellulose (Methocel K 4 M)	200 mg
	mannitol	400 mg
10	maize starch	200 mg
	adipic acid	70 mg
	talc	20 mg
	magnesium stearate	10 mg

15

The active principle, hydroxypropylmethylcellulose, mannitol, maize starch and adipic acid, previously sieved, are mixed for 20 minutes in a suitable mixer. The mixture is then added with magnesium stearate and talc and mixed for further 20 minutes.

20

Bi-layered tablets are prepared using a suitable tabletting machine (Kilian or Manesty) equipped with ogival punches and matrices.

25

The bi-layered tablet, automatically obtained, contains 200 mg of acyclovir in the first effervescent layer and 200 mg of acyclovir in the second layer consisting of hydrophilic, gelifiable and bioadhesive matrix, from which the active component is released in about 24 hours.

30

The dosage forms prepared with the formulations described in example 2, 3 and 4, show good adhesion properties. The adhesion forces, measured with the

apparatus previously described, range from 0.27 to 0.50 kg/cm<sup>2</sup>.

CLAIMS

1. Biocompatible sustained-release vaginal compositions containing antiviral drugs.
- 5 2. Compositions according to claim 1, wherein the antiviral drug is selected from: acycloguanosine (acyclovir) or its salts or derivatives, trifluridine, bromovinyldeoxyuridine, desciclovir, enviroxime, foscarnet sodium, ganciclovir, idoxuridine, inosine pranobex, interferons ( $\alpha$ ,  $\beta$ ,  $\gamma$ ), rimantadine hydrochloride, ribavirine, vidarabine and derivatives, zidovudine or azidothymidine.
- 10 3. Compositions according to claim 2, wherein the antiviral drug is acyclovir its salts and derivatives.
- 15 4. Compositions according to any one of the previous claims in form of hydrophilic tablets, slowly erodible and/or disgregable.
5. Compositions according to claim 1, 2 or 3 in form of bioadhesive hydrophilic tablets.
- 20 6. Compositions according to claim 1, 2 or 3 in form of bi-layered tablets, wherein a first layer is able to release immediately the drug and the second layer provides the sustained release of the drug by means of bioadhesive polymers.
- 25 7. Compositions according to claim 1, 2 or 3 in form of effervescent tablets.
8. Compositions according to claim 1, 2 or 3 in form of vaginal washes containing bioadhesive polymers.
- 30 9. Compositions according to claims 5, 6 or 8 containing biocompatible bioadhesive polymers selected from gelatine, xantanes, scleroglucane, collagene,

pectine and amylopectine, dextrans, hyaluronic or polygalactouronic acid, alginic acid, alginates, polyvinylpyrrolidone, polyvinylalcohol, polyethyleneglycols, polypropyleneglycols and copolymers, 5 polymethylvinylether maleic anhydride copolymer and derivatives, polyacrylic and methacrylic acid derivatives, carboxyvinylpolymers, cellulose derivatives, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose 10 and its salts.

10. Compositions according to claim 1, 2 or 3 containing a polymer or a mixture of polymers biocompatible and/or bioadhesive in amounts varying from 5 to 95 w/w%, but preferably from 15 to 60% with 15 respect to the dosage from weight.

11. Compositions according to claim 1, 2 or 3 containing a biocompatible and/or bioadhesive polymer a mixture of polymers with the same average molecular weight but different substitution characteristics 20 and/or degree of substitution (namely different hydrophilic properties and/or gelation or erosion rates).

## INTERNATIONAL SEARCH REPORT

PCT/EP 92/01655

International Application No.

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC  
 Int.C1. 5 A61K9/00; A61K9/20; A61K31/52

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.C1. 5	A61K
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	EP,A,0 255 902 (TOFCO SA) 17 February 1988 see column 4 - column 5; examples 1-5 see claims ----	1,4,9
X	CHEMICAL ABSTRACTS, vol. 114, no. 10, 11 March 1991, Columbus, Ohio, US; abstract no. 88498z, PARK Y. H. ET AL 'Preparation and evaluation of sustained release oral adhesive type acyclovir tablet' & Yakhak Hoechi ,34(3),155-60 see abstract ----	1-5,9
Y	EP,A,0 020 777 (TEIJIN LIMITED) 7 January 1981 see page 8, line 4 - line 28 see page 15 - page 16; example 4 ----	6-8,11
Y		6,11 -/-

<sup>10</sup> Special categories of cited documents :

- <sup>"A"</sup> document defining the general state of the art which is not considered to be of particular relevance
- <sup>"E"</sup> earlier document but published on or after the international filing date
- <sup>"L"</sup> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- <sup>"O"</sup> document referring to an oral disclosure, use, exhibition or other means
- <sup>"P"</sup> document published prior to the international filing date but later than the priority date claimed

<sup>"T"</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<sup>"X"</sup> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step<sup>"Y"</sup> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.<sup>"A"</sup> document member of the same parent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

16 NOVEMBER 1992

Date of Mailing of this International Search Report

01.12.92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

BOULOIS D.



III. DOCUMENTS CONSIDERED TO BE RELEVANT		(CONTINUED FROM THE SECOND SHEET)	
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.	
Y	BE,A,658 905 (RICHARDSON MERREL INC.) 27 July 1965 see page 6, line 6 - line 17 see page 8; example 1 ---	6	
Y	FR,A,2 355 510 (TOKO YAKUHIN KOGYO KABUSHIKI KAISHA) 20 January 1978 see page 2, line 5 - line 30 see page 6, line 1 - line 15 see page 14; example 22 ---	8	
Y	EP,A,0 088 394 (EISAI CO LTD) 14 September 1983 see page 10 - page 11; examples 1-3 ---	7	
X	CHEMICAL ABSTRACTS, vol. 110, no. 19, 8 May 1989, Columbus, Ohio, US; abstract no. 165630h, HUSSAIN A.S. ET AL 'Body burden' of phosphonoformic acid after topical and vaginal administration to rabbits and beagle dogs' & Methods Find. Exp. Clin. Pharmacol. 11(2) 111-14 see abstract ---	1-3	
X	CHEMICAL ABSTRACTS, vol. 100, no. 13, 26 March 1984, Columbus, Ohio, US; abstract no. 96198c, KERN E.R. ET AL 'Acyclovir treatment of experimental genital herpes simplex virus infections.I. Topical therapy of type 2 and 1 infections of mice' & Antiviral Research 3(4) 253-67 see abstract ---	1	
X	GB,A,2 199 495 (E.R. SQUIBB & SONS INC.) 13 July 1988 see page 3, line 24 - page 4, line 3 see page 5, line 21 - page 6, line 5 see page 7, line 27 - page 10, line 11 see page 14 - page 15; example 1 see claims 1,6,7 ---	1-5,9,10	
Y	US,B,4 389 393 (SCHOR J.M. ET AL) 22 October 1985 see column 8 - column 9; example 5 ---	11	
Y		11	-/-

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	EP,A,0 219 161 (EURAND ITALIA SPA) 22 April 1987 see page 2, column 1, line 36 - line 50 see page 4 - page 5; example 2 ---	11
X	US,A,4 983 393 (COHEN R.S. ET AL.) 8 January 1991 see column 3, line 51 - line 61 see column 4, line 51 - column 5, line 12 see column 8; example 9 see claims 1,4 -----	1,4

**ANNEX TO THE INTERNATIONAL SEARCH REPORT**  
**ON INTERNATIONAL PATENT APPLICATION NO. EP 9201655**  
**SA 63088**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
 The members are as contained in the European Patent Office EDP file on  
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 16/11/92

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0255902	17-02-88	JP-A-	63079816	09-04-88
EP-A-0020777	07-01-81	JP-C- JP-A- JP-B- WO-A- US-A-	1138989 55062012 57029448 8000916 4292299	11-03-83 10-05-80 23-06-82 15-05-80 29-09-81
BE-A-658905	27-07-65	DE-A,C FR-M- GB-A- SE-B- US-A-	1492107 4768 1070492 375236 3388041	17-07-69  14-04-75
FR-A-2355510	20-01-78	JP-C- JP-A- JP-B- AT-B- BE-A- CH-A- DE-A,C GB-A- NL-A- US-A-	1320488 52156913 55038926 360654 855780 638402 2727913 1552521 7706301 4472376	29-05-86 27-12-77 07-10-80 26-01-81 19-12-77 30-09-83 29-12-77 12-09-79 23-12-77 18-09-84
EP-A-0088394	14-09-83	JP-A- CA-A- US-A-	58152809 1217719 4853211	10-09-83 07-02-87 01-08-89
GB-A-2199495	13-07-88	AU-B- AU-A- BE-A- CH-A- DE-A- FR-A- JP-A- NL-A- SE-A- ZA-A-	614069 8264487 1000266 674463 3800256 2609391 63174923 8702956 8800025 8709060	22-08-91 14-07-88 27-09-88 15-06-90 21-07-88 15-07-88 19-07-88 01-08-88 09-07-88 26-05-88

**ANNEX TO THE INTERNATIONAL SEARCH REPORT**  
**ON INTERNATIONAL PATENT APPLICATION NO. EP 9201655**  
**SA 63088**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
 The members are as contained in the European Patent Office EDP file on  
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 16/11/92

Page 2

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-B-4389393	21-06-83	US-A,B	4389393	21-06-83
		BE-A-	896136	01-07-83
		CA-A-	1188614	11-06-85
		CH-A-	655241	15-04-86
		DE-A,C	3309516	01-12-83
		FR-A,B	2523845	30-09-83
		GB-A,B	2117239	12-10-83
		JP-A-	58174311	13-10-83
		JP-A-	61178916	11-08-86
		NL-A-	8301042	17-10-83
		SE-B-	453797	07-03-88
		SE-A-	8301579	27-09-83
EP-A-0219161	22-04-87	AU-B-	591185	30-11-89
		AU-A-	6383186	16-04-87
		DE-A-	3683342	20-02-92
		JP-A-	62123114	04-06-87
		US-A-	4812316	14-03-89
US-A-4983393	08-01-91	US-A-	5069906	03-12-91